Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.

Dennis McGonagle,Iain B McInnes,Atul Deodhar,Georg Schett,May Shawi,Soumya D Chakravarty,Alexa P Kollmeier,Xie L Xu,Shihong Sheng,Stephen Xu,Christopher T Ritchlin,Proton Rahman,Phillip J Mease

ACR open rheumatology（2023）

引用 0|浏览30

暂无评分

摘要

Through 1 year, approximately 75% of guselkumab-randomized patients had complete resolution of dactylitis; patients exhibiting resolution were more likely to achieve other important clinical outcomes. Given the high burden of dactylitis, resolution may be associated with better long-term patient outcomes.

查看译文

关键词

active psoriatic arthritis,resolves dactylitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要